Timolol Maleate Ophthalmic Solution 0.5%

DRUG5 trials

Sponsors

Alcon Research, Aerie Pharmaceuticals, Santen Inc.

Conditions

GlaucomaGlaucoma and Ocular HypertensionOcular HypertensionOpen-angle Glaucoma

Phase 2

AR-12286 in Combination With Latanoprost

CompletedNCT01302249

Aerie PharmaceuticalsGlaucoma, Ocular Hypertension

Start: 2011-02-28End: 2011-12-31Updated: 2014-05-08

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

CompletedNCT01699464

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2012-10-31End: 2013-04-30Updated: 2023-08-22

Phase 3

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT00293787

Alcon ResearchOcular Hypertension, Open-angle Glaucoma

Start: 2004-06-30End: 2005-08-31Updated: 2012-02-14

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

CompletedNCT03691662

Santen Inc.Glaucoma and Ocular Hypertension

Start: 2018-09-27End: 2019-10-23Updated: 2023-08-09

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

CompletedNCT03691649

Santen Inc.Glaucoma and Ocular Hypertension

Start: 2018-09-14End: 2020-09-03Updated: 2023-08-30